Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181885 | 1.00 | TACR1 (0.44) | TACR1MGLLKCNQ2KIF11ALDH1A1 | |
| SCHEMBL6181877 | 1.00 | TACR1 (0.44) | TACR1MGLLKCNQ2KIF11ALDH1A1 | |
| SCHEMBL8060971 | 0.87 | KCNQ2 (0.46) | TACR1MGLLKCNQ2KIF11CCR2 | |
| SCHEMBL8060977 | 0.87 | KCNQ2 (0.46) | TACR1MGLLKCNQ2KIF11CCR2 | |
| SCHEMBL8060970 | 0.87 | KCNQ2 (0.46) | TACR1MGLLKCNQ2KIF11CCR2 | |
| SCHEMBL5474181 | 0.85 | TACR1 (0.41) | TACR1MGLLKCNQ2KIF11ALDH1A1 | |
| SCHEMBL14597712 | 0.85 | TACR1 (0.41) | TACR1MGLLKCNQ2KIF11ALDH1A1 | |
| SCHEMBL1176583 | 0.85 | TACR1 (0.42) | TACR1MGLLKCNQ2KIF11CCR2 | |
| SCHEMBL1176585 | 0.85 | TACR1 (0.42) | TACR1MGLLKCNQ2KIF11CCR2 | |
| SCHEMBL2706185 | 0.85 | TACR1 (0.42) | TACR1MGLLKCNQ2KIF11CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1607389-A1 | 4-protected-amino-2-substituted-1,2,3,4-tetrahydroquinolines as intermediates for CETP inhibitors | Pfizer Products Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050245570-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | DENINNO MICHAEL P | 2005-11-03 | — | — | US | disclosed |
| EP-1114031-B1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6906082-B2 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040092550-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| US-6586448-B1 | Cholesteryl ester transfer protein inhibitors used as antilipemic agents for prophylaxis of cardiovascular disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092550-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | CETP, APOB, NR1H2 | TACR1 1956/4885MGLL 200/4885KCNQ2 1347/4885 |
| US-20050245570-A1 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | CETP, APOB, HDLBP | TACR1 4484/4885MGLL 137/4885KCNQ2 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.